Maxcyte Financials
This page shows Maxcyte (MXCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High-gross-margin revenue remains too small for a fixed operating cost base, making cash burn the central mechanic.
From FY2023 to FY2025, revenue slid from$41.3M to$33.0M . Over the same span, operating loss stayed near$50M and gross margin remained above81.0% , showing the model is not breaking at the product level; spending below gross profit has simply not adjusted to lower sales.
The unit economics are much healthier than the bottom line suggests, because most losses are created after gross profit rather than in delivering revenue. In FY2025, gross profit of
The balance sheet posture is still conservative: liabilities were only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Maxcyte's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Maxcyte scores 0.78, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($137.1M) relative to total liabilities ($31.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Maxcyte passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Maxcyte generates $0.77 in operating cash flow (-$34.4M OCF vs -$44.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Maxcyte generated $33.0M in revenue in fiscal year 2025. This represents a decrease of 14.5% from the prior year.
Maxcyte's EBITDA was -$47.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.4% from the prior year.
Maxcyte reported -$44.6M in net income in fiscal year 2025. This represents a decrease of 8.7% from the prior year.
Maxcyte earned $-0.42 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 7.7% from the prior year.
Cash & Balance Sheet
Maxcyte generated -$36.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 23.6% from the prior year.
Maxcyte held $20.1M in cash against $0 in long-term debt as of fiscal year 2025.
Maxcyte had 107M shares outstanding in fiscal year 2025. This represents an increase of 1.0% from the prior year.
Margins & Returns
Maxcyte's gross margin was 81.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.5 percentage points from the prior year.
Maxcyte's operating margin was -157.1% in fiscal year 2025, reflecting core business profitability. This is down 24.6 percentage points from the prior year.
Maxcyte's net profit margin was -135.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 28.8 percentage points from the prior year.
Maxcyte's ROE was -26.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 6.1 percentage points from the prior year.
Capital Allocation
Maxcyte invested $20.8M in research and development in fiscal year 2025. This represents a decrease of 6.3% from the prior year.
Maxcyte invested $1.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 7.1% from the prior year.
MXCT Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M+32.2% | $7.3M+6.9% | $6.8M-19.7% | $8.5M-18.1% | $10.4M+19.5% | $8.7M+6.5% | $8.2M-21.7% | $10.4M |
| Cost of Revenue | $1.6M-2.5% | $1.6M+0.9% | $1.6M+5.1% | $1.5M+1.5% | $1.5M-34.4% | $2.3M+18.3% | $1.9M+29.6% | $1.5M |
| Gross Profit | $8.1M+42.0% | $5.7M+8.7% | $5.2M-25.1% | $7.0M-21.4% | $8.9M+38.7% | $6.4M+2.8% | $6.2M-30.3% | $8.9M |
| R&D Expenses | $3.9M+15.7% | $3.3M-37.3% | $5.3M-15.2% | $6.3M+6.2% | $5.9M+27.9% | $4.6M-13.2% | $5.3M-5.4% | $5.6M |
| SG&A Expenses | $6.0M+8.8% | $5.5M-9.1% | $6.0M-25.4% | $8.1M-5.2% | $8.5M+18.3% | $7.2M-7.0% | $7.7M+1.4% | $7.6M |
| Operating Income | -$6.2M+44.9% | -$11.2M+20.7% | -$14.1M+0.5% | -$14.2M-15.7% | -$12.3M+4.7% | -$12.9M+8.2% | -$14.1M-17.4% | -$12.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.8M+50.5% | -$9.6M+22.7% | -$12.4M-0.5% | -$12.4M-20.4% | -$10.3M+3.2% | -$10.6M+8.3% | -$11.6M-23.3% | -$9.4M |
| EPS (Diluted) | $-0.04 | N/A | $-0.120.0% | $-0.12-20.0% | $-0.10 | N/A | $-0.11-22.2% | $-0.09 |
MXCT Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $194.5M-4.0% | $202.5M-5.1% | $213.5M-2.9% | $219.8M-4.4% | $230.0M-4.0% | $239.5M-3.7% | $248.6M-1.1% | $251.5M |
| Current Assets | $122.9M+3.9% | $118.4M-5.0% | $124.6M-13.0% | $143.2M-8.0% | $155.7M-9.3% | $171.7M-0.7% | $172.9M-1.6% | $175.6M |
| Cash & Equivalents | $14.6M-27.5% | $20.1M+54.7% | $13.0M-14.8% | $15.2M-34.9% | $23.4M-16.1% | $27.9M-24.6% | $37.0M-1.5% | $37.5M |
| Inventory | $7.6M+1.1% | $7.5M-0.8% | $7.6M-4.1% | $7.9M-4.1% | $8.3M-7.2% | $8.9M-14.2% | $10.4M-6.9% | $11.2M |
| Accounts Receivable | $4.2M+21.2% | $3.5M-57.8% | $8.3M+44.4% | $5.8M+4.1% | $5.5M+18.0% | $4.7M+2.7% | $4.6M-0.5% | $4.6M |
| Goodwill | N/A | N/A | $3.6M-5.2% | $3.7M-4.4% | $3.9M | N/A | N/A | N/A |
| Total Liabilities | $26.6M-14.3% | $31.0M-6.6% | $33.2M+14.4% | $29.0M-5.0% | $30.5M-8.0% | $33.2M-5.9% | $35.3M+16.8% | $30.2M |
| Current Liabilities | $10.2M-28.4% | $14.3M-11.4% | $16.1M+39.4% | $11.6M-9.3% | $12.7M-19.3% | $15.8M-10.5% | $17.6M+43.6% | $12.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $167.9M-2.1% | $171.5M-4.9% | $180.3M-5.5% | $190.7M-4.4% | $199.4M-3.3% | $206.3M-3.3% | $213.3M-3.6% | $221.3M |
| Retained Earnings | -$266.2M-1.8% | -$261.5M-3.8% | -$251.9M-5.2% | -$239.5M-5.4% | -$227.1M-4.7% | -$216.9M-5.1% | -$206.3M-5.9% | -$194.7M |
MXCT Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.2M-203.8% | -$2.7M+63.9% | -$7.5M+24.3% | -$9.9M+31.6% | -$14.4M-84.3% | -$7.8M-78.1% | -$4.4M+9.2% | -$4.8M |
| Capital Expenditures | $72K-68.8% | $231K-23.0% | $300K-48.6% | $584K-10.6% | $653K+344.2% | $147K-63.8% | $406K+38.1% | $294K |
| Free Cash Flow | -$8.2M-182.2% | -$2.9M+62.4% | -$7.8M+25.7% | -$10.4M+30.7% | -$15.1M-89.1% | -$8.0M-66.1% | -$4.8M+6.5% | -$5.1M |
| Investing Cash Flow | $2.7M-72.6% | $9.7M+86.4% | $5.2M+237.6% | $1.5M-83.9% | $9.5M+672.3% | -$1.7M-146.1% | $3.6M-81.4% | $19.4M |
| Financing Cash Flow | $5K-95.2% | $105K+650.0% | $14K-90.9% | $154K-59.8% | $383K-7.0% | $412K+80.7% | $228K-68.0% | $713K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MXCT Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.7%+5.8pp | 78.0%+1.3pp | 76.6%-5.5pp | 82.1%-3.4pp | 85.6%+11.8pp | 73.8%-2.6pp | 76.4%-9.3pp | 85.7% |
| Operating Margin | -64.1%+89.7pp | -153.8%+53.4pp | -207.2%-39.9pp | -167.2%-48.9pp | -118.3%+30.1pp | -148.4%+23.7pp | -172.1%-57.4pp | -114.8% |
| Net Margin | -49.2%+82.2pp | -131.4%+50.4pp | -181.8%-36.6pp | -145.3%-46.5pp | -98.8%+23.2pp | -121.9%+19.6pp | -141.6%-51.7pp | -89.9% |
| Return on Equity | -2.8%+2.8pp | -5.6%+1.3pp | -6.9%-0.4pp | -6.5%-1.3pp | -5.1%-0.0pp | -5.1%+0.3pp | -5.4%-1.2pp | -4.2% |
| Return on Assets | -2.4%+2.3pp | -4.7%+1.1pp | -5.8%-0.2pp | -5.6%-1.2pp | -4.5%-0.0pp | -4.4%+0.2pp | -4.7%-0.9pp | -3.7% |
| Current Ratio | 12.04+3.7 | 8.30+0.6 | 7.74-4.7 | 12.39+0.2 | 12.23+1.3 | 10.88+1.1 | 9.81-4.5 | 14.31 |
| Debt-to-Equity | 0.16-0.0 | 0.180.0 | 0.18+0.0 | 0.150.0 | 0.150.0 | 0.160.0 | 0.17+0.0 | 0.14 |
| FCF Margin | -85.4%-45.4pp | -40.0%+73.6pp | -113.6%+9.1pp | -122.7%+22.3pp | -145.0%-53.3pp | -91.7%-32.9pp | -58.8%-9.6pp | -49.2% |
Similar Companies
Frequently Asked Questions
What is Maxcyte's annual revenue?
Maxcyte (MXCT) reported $33.0M in total revenue for fiscal year 2025. This represents a -14.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Maxcyte's revenue growing?
Maxcyte (MXCT) revenue declined by 14.5% year-over-year, from $38.6M to $33.0M in fiscal year 2025.
Is Maxcyte profitable?
No, Maxcyte (MXCT) reported a net income of -$44.6M in fiscal year 2025, with a net profit margin of -135.1%.
What is Maxcyte's EBITDA?
Maxcyte (MXCT) had EBITDA of -$47.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Maxcyte's gross margin?
Maxcyte (MXCT) had a gross margin of 81.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Maxcyte's operating margin?
Maxcyte (MXCT) had an operating margin of -157.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Maxcyte's net profit margin?
Maxcyte (MXCT) had a net profit margin of -135.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Maxcyte's return on equity (ROE)?
Maxcyte (MXCT) has a return on equity of -26.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Maxcyte's free cash flow?
Maxcyte (MXCT) generated -$36.2M in free cash flow during fiscal year 2025. This represents a -23.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Maxcyte's operating cash flow?
Maxcyte (MXCT) generated -$34.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Maxcyte's total assets?
Maxcyte (MXCT) had $202.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Maxcyte's capital expenditures?
Maxcyte (MXCT) invested $1.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Maxcyte spend on research and development?
Maxcyte (MXCT) invested $20.8M in research and development during fiscal year 2025.
What is Maxcyte's current ratio?
Maxcyte (MXCT) had a current ratio of 8.30 as of fiscal year 2025, which is generally considered healthy.
What is Maxcyte's debt-to-equity ratio?
Maxcyte (MXCT) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Maxcyte's return on assets (ROA)?
Maxcyte (MXCT) had a return on assets of -22.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Maxcyte's cash runway?
Based on fiscal year 2025 data, Maxcyte (MXCT) had $20.1M in cash against an annual operating cash burn of $34.4M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Maxcyte's Altman Z-Score?
Maxcyte (MXCT) has an Altman Z-Score of 0.78, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Maxcyte's Piotroski F-Score?
Maxcyte (MXCT) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Maxcyte's earnings high quality?
Maxcyte (MXCT) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Maxcyte?
Maxcyte (MXCT) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.